GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Qualis Innovations Inc (OTCPK:QLIS) » Definitions » Cash-to-Debt

Qualis Innovations (Qualis Innovations) Cash-to-Debt : 0.22 (As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Qualis Innovations Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Qualis Innovations's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.22.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Qualis Innovations couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Qualis Innovations's Cash-to-Debt or its related term are showing as below:

QLIS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.22   Med: 2.26   Max: No Debt
Current: 0.22

During the past 9 years, Qualis Innovations's highest Cash to Debt Ratio was No Debt. The lowest was 0.22. And the median was 2.26.

QLIS's Cash-to-Debt is ranked worse than
85.38% of 862 companies
in the Medical Devices & Instruments industry
Industry Median: 1.935 vs QLIS: 0.22

Qualis Innovations Cash-to-Debt Historical Data

The historical data trend for Qualis Innovations's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Qualis Innovations Cash-to-Debt Chart

Qualis Innovations Annual Data
Trend Jul06 Jul07 Jul08 Jul09 Jul10 Dec11 Dec21 Dec22 Dec23
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only No Debt 1.01 No Debt 2.26 0.22

Qualis Innovations Quarterly Data
Jul10 Oct10 Jan11 Apr11 Sep11 Dec11 Mar12 Jun12 Sep12 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.26 No Debt No Debt No Debt 0.22

Competitive Comparison of Qualis Innovations's Cash-to-Debt

For the Medical Devices subindustry, Qualis Innovations's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Qualis Innovations's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Qualis Innovations's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Qualis Innovations's Cash-to-Debt falls into.


Qualis Innovations Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Qualis Innovations's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio= Cash, Cash Equivalents, Marketable Securities / Total Debt
= Cash, Cash Equivalents, Marketable Securities / (Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation)
=0.002 / (0.009 + 0)
=0.22

Qualis Innovations's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio= Cash, Cash Equivalents, Marketable Securities / Total Debt
= Cash, Cash Equivalents, Marketable Securities / (Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation)
=0.002 / (0.009 + 0)
=0.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Qualis Innovations  (OTCPK:QLIS) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Qualis Innovations Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Qualis Innovations's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Qualis Innovations (Qualis Innovations) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Qualis Innovations Inc (OTCPK:QLIS) » Definitions » Cash-to-Debt
Comparable Companies
VYCO TIVC DYNT BBLG NAOV VTAK INBS NXL THMO ESMC ABT SYK MDT BSX SZSE:300760 DXCM EW ZBH STE XAMS:PHIA
Traded in Other Exchanges
N/A
Address
225 Wilmington West Chester Pike, Suite 200, No.145, Chadds Ford, PA, USA, 19317
Website
https://www.qualisinnovations.com
Qualis Innovations Inc. is the holding company of mPathix Health, Inc. The company is focused on the development, production, and distribution of multi-modal pain management and Central Nervous System related solutions. It develops pain management products using a modality agnostic, virtual operating model. The company is developing a product designed to address the unmet needs of patients who seek alternatives to traditional pain medications and interventions or adjunctive therapies to their current treatment regimen.
Executives
Bin Wang director 112 RICO DR. NORTH, MORGANVILLE NJ 07751